Compare Stocks

Date Range: 

 Ascendis Pharma A/SEvotecTG TherapeuticsGW PharmaceuticalsArrowhead Pharmaceuticals
SymbolNASDAQ:ASNDOTCMKTS:EVTCYNASDAQ:TGTXNASDAQ:GWPHNASDAQ:ARWR
Price Information
Current Price$138.18$83.16$41.48$218.96$66.47
52 Week RangeBuyHoldBuyHoldBuy
MarketRank™
Overall Score1.50.51.81.31.5
Analysis Score3.50.03.41.13.4
Community Score2.62.53.33.02.5
Dividend Score0.00.00.00.00.0
Ownership Score0.80.01.71.71.7
Earnings & Valuation Score0.60.00.60.60.0
Analyst Ratings
Consensus RecommendationBuyHoldBuyHoldBuy
Consensus Price Target$192.22N/A$63.33$204.09$85.31
% Upside from Price Target39.11% upsideN/A52.68% upside-6.79% downside28.34% upside
Trade Information
Market Cap$7.43 billion$6.84 billion$5.83 billion$6.86 billion$6.90 billion
Beta0.771.132.282.151.62
Average Volume214,5828591,502,873899,737787,455
Sales & Book Value
Annual Revenue$14.98 million$500.07 million$150,000.00$311.33 million$87.99 million
Price / Sales495.8113.6838,876.7222.0578.41
CashflowN/A$1.52 per shareN/A$0.01 per shareN/A
Price / CashN/A54.59N/A18,588.22N/A
Book Value$15.87 per share$7.08 per share$0.39 per share$23.48 per share$4.51 per share
Price / Book8.7111.75106.369.3314.74
Profitability
Net Income$-244,180,000.00$42.64 million$-172,870,000.00$-9,020,000.00$-84,550,000.00
EPS($5.25)$0.56($1.83)($0.24)($0.84)
Trailing P/E RatioN/A462.03N/AN/AN/A
Forward P/E RatioN/AN/A608.22N/A
P/E GrowthN/AN/AN/AN/AN/A
Net Margins-4,042.79%3.92%-151,798.69%-11.05%-96.09%
Return on Equity (ROE)-55.72%3.96%-223.96%-7.46%-17.37%
Return on Assets (ROA)-49.42%1.61%-108.08%-6.13%-15.19%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/A0.90%0.09%0.01%N/A
Current Ratio14.80%2.19%3.35%5.13%7.92%
Quick Ratio14.80%2.13%3.35%4.31%7.92%
Ownership Information
Institutional Ownership PercentageN/AN/A65.73%81.00%65.52%
Insider Ownership Percentage40.00%N/A13.20%3.10%4.00%
Miscellaneous
Employees4823,5722721,161232
Shares Outstanding53.75 million82.28 million140.59 million31.35 million103.79 million
Next Earnings Date5/18/2021 (Estimated)5/13/2021 (Estimated)5/10/2021 (Estimated)8/5/2021 (Estimated)8/4/2021 (Estimated)
OptionableOptionableNot OptionableOptionableOptionableOptionable
SourceHeadline
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Releases  Earnings Results, Misses Expectations By $0.60 EPSArrowhead Pharmaceuticals (NASDAQ:ARWR) Releases Earnings Results, Misses Expectations By $0.60 EPS
americanbankingnews.com - May 4 at 11:46 PM
Arrowhead Pharmaceuticals Reports Fiscal 2021 Second Quarter ResultsArrowhead Pharmaceuticals Reports Fiscal 2021 Second Quarter Results
finance.yahoo.com - May 4 at 7:17 PM
Is Arrowhead Pharmaceuticals (ARWR) A Smart Long-Term Buy?Is Arrowhead Pharmaceuticals (ARWR) A Smart Long-Term Buy?
finance.yahoo.com - May 3 at 2:13 PM
Should You Retain Your Arrowhead Pharmaceuticals (ARWR) Position?Should You Retain Your Arrowhead Pharmaceuticals (ARWR) Position?
finance.yahoo.com - April 30 at 2:10 PM
ARWR: Raising target price to $84.00ARWR: Raising target price to $84.00
finance.yahoo.com - April 29 at 8:24 PM
Arrowheads ARO-AAT Treatment Associated With Improved Fibrosis In Patients With Alpha-1 Liver DiseaseArrowhead's ARO-AAT Treatment Associated With Improved Fibrosis In Patients With Alpha-1 Liver Disease
finance.yahoo.com - April 28 at 6:33 PM
Arrowhead Announces Improvement in Fibrosis after ARO-AAT Treatment in Patients with Alpha-1 Liver DiseaseArrowhead Announces Improvement in Fibrosis after ARO-AAT Treatment in Patients with Alpha-1 Liver Disease
finance.yahoo.com - April 28 at 8:32 AM
Is Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) a Suitable Stock for New Investors Now?Is Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) a Suitable Stock for New Investors Now?
stocksregister.com - April 24 at 9:03 AM
When would be the best time to Buy Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) stock?When would be the best time to Buy Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) stock?
stocksregister.com - April 18 at 3:55 AM
Interesting ARWR Put And Call Options For December 17thInteresting ARWR Put And Call Options For December 17th
nasdaq.com - April 16 at 3:38 PM
Notable Two Hundred Day Moving Average Cross - ARWRNotable Two Hundred Day Moving Average Cross - ARWR
nasdaq.com - April 12 at 1:32 PM
 Analysts Anticipate Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Will Post Quarterly Sales of $91.23 Million Analysts Anticipate Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Will Post Quarterly Sales of $91.23 Million
americanbankingnews.com - April 11 at 1:54 AM
Arrowhead Pharmaceuticals is Now Oversold (ARWR)Arrowhead Pharmaceuticals is Now Oversold (ARWR)
nasdaq.com - March 5 at 5:51 PM
Arrowhead Pharmaceuticals Files IND to Begin Phase 2b Study of ARO-APOC3 in Patients with Severe HypertriglyceridemiaArrowhead Pharmaceuticals Files IND to Begin Phase 2b Study of ARO-APOC3 in Patients with Severe Hypertriglyceridemia
finance.yahoo.com - March 1 at 9:39 AM
Accredited Virtual Event Preview- Corning, Cookware CovidAccredited Virtual Event Preview- Corning, Cookware Covid
finance.yahoo.com - February 26 at 2:19 PM
These Analysts Just Made A Substantial Downgrade To Their Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) EPS ForecastsThese Analysts Just Made A Substantial Downgrade To Their Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) EPS Forecasts
nasdaq.com - February 12 at 7:15 AM
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Analysts Just Slashed This Years EstimatesArrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Analysts Just Slashed This Year's Estimates
finance.yahoo.com - February 12 at 7:15 AM
ARWR: Multiple Data Readouts in 2021…ARWR: Multiple Data Readouts in 2021…
finance.yahoo.com - February 9 at 6:39 PM
Arrowhead Pharmaceuticals, Inc (ARWR) Q1 2021 Earnings Call TranscriptArrowhead Pharmaceuticals, Inc (ARWR) Q1 2021 Earnings Call Transcript
finance.yahoo.com - February 5 at 10:30 PM
First Week of September 17th Options Trading For Arrowhead Pharmaceuticals (ARWR)First Week of September 17th Options Trading For Arrowhead Pharmaceuticals (ARWR)
nasdaq.com - January 19 at 5:03 PM
Arrowhead Pharmaceuticals to Webcast Fiscal 2021 First Quarter ResultsArrowhead Pharmaceuticals to Webcast Fiscal 2021 First Quarter Results
finance.yahoo.com - January 19 at 5:03 PM
ARWR Jan 2021 65.000 callARWR Jan 2021 65.000 call
uk.finance.yahoo.com - December 31 at 11:12 PM
ARWR Jan 2021 25.000 putARWR Jan 2021 25.000 put
uk.finance.yahoo.com - December 31 at 11:12 PM
ARWR Feb 2021 105.000 callARWR Feb 2021 105.000 call
uk.finance.yahoo.com - December 31 at 1:07 PM
ARWR Jan 2023 30.000 putARWR Jan 2023 30.000 put
uk.finance.yahoo.com - December 31 at 12:28 AM
DateCompanyBrokerageAction
3/30/2021Ascendis Pharma A/SOppenheimerDowngrade
3/18/2021Ascendis Pharma A/SCanaccord GenuityBoost Price Target
3/17/2021Ascendis Pharma A/SCredit Suisse GroupLower Price Target
3/11/2021Ascendis Pharma A/SStifel NicolausInitiated Coverage
12/17/2020Ascendis Pharma A/SBerenberg BankInitiated Coverage
11/13/2020Ascendis Pharma A/SMorgan StanleyBoost Price Target
11/12/2020Ascendis Pharma A/SWells Fargo & CompanyBoost Price Target
11/12/2020Ascendis Pharma A/SSVB LeerinkBoost Price Target
9/30/2020Ascendis Pharma A/SWedbushBoost Price Target
9/14/2020Ascendis Pharma A/SJPMorgan Chase & Co.Initiated Coverage
5/20/2020Ascendis Pharma A/SCSFBBoost Price Target
4/22/2021EvotecDeutsche Bank AktiengesellschaftReiterated Rating
3/5/2021EvotecCitigroupDowngrade
1/28/2021EvotecRoyal Bank of CanadaDowngrade
4/26/2021TG TherapeuticsHC WainwrightBoost Price Target
4/26/2021TG TherapeuticsThe Goldman Sachs GroupInitiated Coverage
2/5/2021TG TherapeuticsB. RileyBoost Price Target
10/28/2020TG TherapeuticsCantor FitzgeraldBoost Price Target
6/5/2020TG TherapeuticsEvercore ISIInitiated Coverage
2/22/2021GW PharmaceuticalsRaymond JamesReiterated Rating
2/3/2021GW PharmaceuticalsNorthland SecuritiesDowngrade
2/3/2021GW PharmaceuticalsNeedham & Company LLCReiterated Rating
8/10/2020GW PharmaceuticalsGuggenheimLower Price Target
8/7/2020GW PharmaceuticalsBank of AmericaReiterated Rating
2/5/2021Arrowhead PharmaceuticalsPiper SandlerBoost Price Target
2/5/2021Arrowhead PharmaceuticalsChardan CapitalBoost Price Target
12/21/2020Arrowhead PharmaceuticalsRobert W. BairdDowngrade
12/15/2020Arrowhead PharmaceuticalsUBS GroupInitiated Coverage
11/19/2020Arrowhead PharmaceuticalsSmith Barney CitigroupInitiated Coverage
11/19/2020Arrowhead PharmaceuticalsCitigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellInitiated Coverage
(Data available from 5/6/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.